ADURO BIOTECH, INC. (NASDAQ:ADRO) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

Set forth below are the proposals voted upon at the Annual
Meeting (the Annual Meeting) of Stockholders of Aduro Biotech,
Inc. (the Company) held on June8, 2017 at 740 Heinz Avenue,
Berkeley, California 94710, along with the final voting results
thereon:

Proposal 1To elect the two Class II directors
named below to serve until the 2020 Annual Meeting of
Stockholders or until their respective successors have been duly
elected and qualified. Each of the two named nominees was so
elected, with the votes thereon at the Annual Meeting as follows:

Proposal 2 To ratify the selection by the Audit
Committee of the Board of Directors of Deloitte Touche LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017. This proposal was approved
by the requisite vote, with the votes thereon at the Annual
Meeting as follows:

About ADURO BIOTECH, INC. (NASDAQ:ADRO)

Aduro Biotech, Inc. is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. Its LADD product candidates include CRS-207, ADU-623, ADU-741 and ADU-214. Its STING Activator product candidates include ADU-S100. Its LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Its STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. Its B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.